Table 1.
Baseline characteristics of participants in a randomized controlled trial that tested the effects of a mobile health–based, pharmacist-led intervention on medication errors and adverse events (TRANSAFE Rx)
| Characteristic | All (n=136) | Control (n=68) | Intervention (n=68) |
|---|---|---|---|
| Mean age (SD), yr | 51±13 | 51±14 | 50±12 |
| Male, n (%) | 77 (57) | 42 (62) | 35 (52) |
| Female, n (%) | 59 (43) | 26 (38) | 33 (49) |
| White, n (%) | 46 (34) | 19 (28) | 27 (40) |
| Black, n (%) | 87 (64) | 47 (69) | 40 (59) |
| Hispanic, n (%) | 3 (2) | 2 (3) | 1 (2) |
| Height (SD), cm | 172±11 | 173±11 | 171±11 |
| Mean weight (SD), kg | 89±19 | 88±19 | 90±20 |
| History of diabetes, n (%) | 54 (40) | 35 (52) | 19 (2) |
| History of hypertension, n (%) | 124 (92) | 61 (91) | 63 (93) |
| Dialysis at transplant, n (%) | 114 (84) | 56 (84) | 58 (85) |
| Hemodialysis | 80 (7) | 42 (75) | 38 (66) |
| Peritoneal dialysis | 34 (30) | 14 (25) | 20 (35) |
| Mean years on dialysis (SD), yr | 4.0±2.8 | 4.0±3.0 | 3.9±2.6 |
| Mean cPRA at transplant (SD), % | 49.9±39.7 | 49.7±41.0 | 50.0±38.6 |
| Median HLA mismatch (IQR) | 5 (4–5) | 4 (4–5) | 5 (3–5) |
| Mean cold ischemic time (SD), h | 17.0±8.0 | 17.5±8.0 | 16.4±8.0 |
| Mean warm ischemic time (SD), min | 38.0±13.9 | 38.0±15.8 | 38.1±11.9 |
| Basiliximab induction, n (%) | 51 (38) | 26 (38) | 25 (37) |
| Thymoglobulin induction, n (%) | 85 (63) | 42 (62) | 43 (63) |
| Delayed graft function, n (%) | 26 (20) | 8 (13) | 18 (27) |
| CMV serostatus (D/R), n (%) | |||
| Neg/Neg | 12 (9) | 7 (10) | 5 (7) |
| Neg/Pos | 35 (26) | 22 (32) | 13 (19) |
| Pos/Pos | 59 (43) | 30 (44) | 29 (43) |
| Pos/Neg | 26 (19) | 8 (12) | 18 (27) |
| Unknown | 4 (3) | 1 (2) | 3 (4) |
| Mean donor age (SD), yr | 35±14 | 37±15 | 33±12 |
| Donor sex, n (%) | |||
| Male | 88 (65) | 47 (69) | 41 (60) |
| Female | 47 (35) | 20 (29) | 27 (40) |
| Missing | 1 (1) | 1 (2) | 0 (0) |
| Donor race, n (%) | |||
| White | 81 (60) | 42 (62) | 39 (57) |
| Black | 35 (26) | 16 (24) | 19 (28) |
| Other | 20 (15) | 10 (1) | 10 (15) |
| Living donor, n (%) | 13 (10) | 7 (10) | 6 (9) |
| DCD donor, n (%) | 16 (13) | 11 (18) | 5 (8) |
| Mean KDRI in deceased donors (SD) | 41.6±24.5 | 46.2±24.8 | 37.1±23.4 |
| Acute rejection history, n (%) | 6 (4) | 3 (4) | 3 (4) |
| Hospitalization history, n (%) | 33 (24) | 16 (24) | 17 (25) |
| Mean clinic visit history (SD) | 5.9±4.7 | 5.7±4.3 | 6.1±5.0 |
| Median ambulatory procedures history (IQR) | 0 (0, 2) | 0 (0, 2) | 0 (0, 2) |
| Yr from transplant to enrollment (SD) | 1±1 | 1±1 | 1±1 |
cPRA, calculated panel reactive antibodies; HLA, human leukocyte antigen; IQR, interquartile range; CMV, cytomegalovirus; D, donor; R, recipient; Neg, negative; Pos, positive; DCD, deceased; KDRI, Kidney Donor Risk Index.